ClinicalTrials.Veeva

Menu

Unbound Cloxacillin Concentrations During Continuous Infusion (KLONC)

E

Emeli Månsson

Status and phase

Begins enrollment in 4 months
Phase 4

Conditions

Staphylococcal Infections

Treatments

Diagnostic Test: Unbound cloxacillin concentration

Study type

Interventional

Funder types

Other

Identifiers

NCT06848387
992496/KLONC

Details and patient eligibility

About

Cloxacillin is the first-line choice for the treatment of severe infections caused by the bacterium Staphylococcus aureus in Sweden. Over the past year, cloxacillin is increasingly administred through continuous infusion. In this study, the free (unbound) concentration of cloxacillin when administered as a continuous infusion will be measured to ensure that the free concentration is neither too high nor too low. A PK/PD model will be developed to predict which dosage of cloxacillin is appropriate for an individual based on age, gender, kidney function, and serum-protein level.

Enrollment

25 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Age 18 years or older
  • Treating physician has decided to start continuous infusion of cloxacillin

Exclusion criteria

  • Unwilling or unable to provide written informed consent

Trial design

Primary purpose

Other

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

25 participants in 1 patient group

Treatment with cloxacillin as continuous infusion via elastomeric pump
Experimental group
Description:
Additional monitoring procedures performed: blood samples drawn before, after 4h, after 24h, and after 48h of continuous infusion of cloxacillin.
Treatment:
Diagnostic Test: Unbound cloxacillin concentration

Trial contacts and locations

0

Loading...

Central trial contact

Emeli Månsson, PhD; Karl-Johan Lindner, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems